Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: A meta-analysis

Zhang, Hailong; Ruan, Linhui; Zheng, Li-Mou; Whyte, David B.; Tzeng, Chi-Meng; Zhou, Xi-Wu

doi:10.1016/j.lungcan.2012.01.005

Cited by 69 publications

(49 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Agents that are part of standard of care for colorectal cancer, as mentioned above, including fluorouracil and irinotecan are suggested to benefit a high portion of patients as many patients carry a favorable biomarker profile. 20,21 Agents not routinely considered including temozolomide, gemcitabine, taxanes as well as anthracyclines have suggestion of improved activity against tumors carrying low MGMT, 22 RRM1, 23 TUBB3 24 and high TOPO2A IHCs respectively. 25 Mutation rates vary significantly in colorectal cancer such that APC and TP53 are mutated in more than half of patients, while more than half of the genes tested carry a mutation rate of less than 1%.…”

Section: Discussionmentioning

confidence: 99%

Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites

El‐Deiry

Vijayvergia

Xiu

et al. 2015

Cancer Biology & Therapy

View full text Add to dashboard Cite

Metastatic colorectal cancer (mCRC) carries a poor prognosis with an overall 5-year survival of 13.1%. Therapies guided by tumor profiling have suggested benefit in advanced cancer. We used a multiplatform molecular profiling (MP) approach to identify key molecular changes that may provide therapeutic options not typically considered in mCRC. We evaluated 6892 mCRC referred to Caris Life Sciences by MP including sequencing (Sanger/NGS), immunohistochemistry (IHC) and in-situ hybridization (ISH). mCRC metastases to liver, brain, ovary or lung (n D 1507) showed differential expression of markers including high protein expression of TOPO1 (52%) and/or low RRM1 (57%), TS (71%) and MGMT (39%), suggesting possible benefit from irinotecan, gemcitabine, 5FU/capecitabine and temozolomide, respectively. Lung metastases harbored a higher Her2 protein expression than the primary colon tumors (4% vs. 1.8%, p D 0.028). Brain and lung metastases had higher KRAS mutations than other sites (65% vs 59% vs 47%, respectively, p D 0.07, <0.01), suggesting poor response to anti-EGFR therapies. BRAF-mutated CRC (n D 455) showed coincident high protein expression of RRM1 (56%), TS (53%) and low PDGFR (22%) as compared with BRAF wild-type tumors. KRAS-mutated mCRC had higher protein expression of c-MET (47% vs. 36%) and lower MGMT (56% vs. 63%), suggesting consideration of c-MET inhibitors and temozolomide. KRAS-mutated CRC had high TUBB3 (42% vs. 33%) and low Her2 by IHC (0.5%) and HER2 by FISH (3%, p <0.05). CRC primaries had a lower incidence of PIK3CA and BRAF mutations in rectal cancer versus colon cancer (10% and 3.3%, respectively). MP of 6892 CRCs identified significant differences between primary and metastatic sites and among BRAF/KRAS sub-types. Our findings are hypothesis generating and need to be examined in prospective studies. Specific therapies may be considered for different actionable targets in mCRC as revealed by MP.

show abstract

Section: Discussionmentioning

confidence: 99%

Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites

El‐Deiry

Vijayvergia

Xiu

et al. 2015

Cancer Biology & Therapy

View full text Add to dashboard Cite

show abstract

“…Patients with lower levels of β-tubulin III are more sensitive to docetaxel treatment [19, 20], while β-tubulin III high expression represents an independent risk factor for the poor progression-free survival (PFS) of cancer patients receiving such treatment [21]. Collectively, these findings demonstrate that the β-tubulin III mRNA level can be used as an independent predictive biomarker for the outcome of the paclitaxel-/vinorelbine-based chemotherapy [22]. …”

Section: Introductionmentioning

confidence: 99%

A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancer

Zhang

Zhu

Zhang

et al. 2014

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

Purpose To assess the therapeutic value of biomarker-guided chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).MethodsEighty-five NSCLC patients at stage IIIb or IV were divided into two groups based on the feasibility of biomarker analysis. Group A included patients with biomarker data (n = 41); Group B were patients without biomarker results (n = 44). Tumor samples obtained by fiberoptic bronchoscopy and computerized tomography-guided needle biopsy were analyzed by immunohistochemistry for intratumoral level of excision repair cross-complementing gene 1 (ERCC1), ribonucleotide reductase M1 (RRM1), and β-tubulin III. Chemotherapy regimens in Group A were determined according to the status of molecular signatures, whereas a standard gemcitabine plus cisplatin regimen was used for Group B. Tumor response, patient survival, and adverse effects were monitored for both groups.ResultsThe overall response rate, defined as complete response plus partial response, was 56.1 % for Group A, significantly higher than that in Group B (31.8 %; P = 0.024). The median progression-free survival (PFS) time was 5.2 months for Group A, significantly longer than that of Group B (4.1 months; P = 0.026). The 1-year survival rate of Group A was 65.9 %, significantly higher than that of Group B (40.9 %; P = 0.021), whereas the median overall survival times were 13.5 versus 12.5 months for Groups A and B, respectively (P = 0.483). The adverse effects in the two groups were essentially the same.ConclusionsBiomarker-tailored chemotherapy based on ERCC1, RRM1, and β-tubulin III expression showed significantly increased response rate, median PFS time, and 1-year survival rate in patients with NSCLC.

show abstract

“…It has been previously reported that the expression of excision repair cross-complementation group 1 (ERCC1) isoform is a potential biomarker of the efficacy of cisplatinbased chemotherapy (16). Also, Zhang et al (17) showed the expression of the class III b-tubulin was associated with chemosensitivity of paclitaxel. We did not check the expression of these proteins in our case, and further study may be required.…”

Section: Discussionmentioning

confidence: 99%

A Case of Pulmonary Mucoepidermoid Carcinoma Responding to Carboplatin and Paclitaxel

Sonobe

Inoue

Tachibana

et al. 2014

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

A 59-year-old man was admitted to our hospital with dyspnea and cough. A large polypoid tumor was observed in the lower trachea and bronchoscopic polypectomy was performed using a snare to relieve symptoms. The tumor was diagnosed as a high grade mucoepidermoid carcinoma mainly by the histology of piecemeal specimens obtained by bronchoscopic resection. The primary lesion involved the trachea and the main bronchus, and there were multiple metastases in the lung. The patient was treated with the combination of carboplatin and paclitaxel. After four cycles of chemotherapy, the tumors were significantly reduced. He remains well without evidence of tumor progression for 25 months. This case suggests that the combination chemotherapy of carboplatin and paclitaxel can be an option for treatment of pulmonary mucoepidermoid carcinoma.

show abstract

Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: A meta-analysis

Cited by 69 publications

References 18 publications

Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites

Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites

A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancer

A Case of Pulmonary Mucoepidermoid Carcinoma Responding to Carboplatin and Paclitaxel

Contact Info

Product

Resources

About